 BETHLEHEM, Pa., Dec. 21, 2020 GLOBE NEWSWIRE -- OraSure Technologies, Inc. NASDAQ: OSUR, a leader in point-of-care diagnostic tests and specimen collection devices, today disclosed that the U.S. Food and Drug Administration FDA has requested additional information as part of its review of the Companys application for Emergency Use Authorization EUA for its laboratory-based oral fluid SARS-CoV-2 antibody test. The OraSure SARS-CoV-2 Antibody ELISA is intended for qualitative detection of total antibodies to SARS-CoV-2 in human oral fluid specimens collected with the OraSure Oral Antibody Collection Device. 